Alnylam Pharmaceuticals Inc. (ALNY) Receives Consensus Rating of “Buy” from Brokerages
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has earned a consensus rating of “Buy” from the sixteen analysts that are currently covering the company. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $59.85.
Several research analysts recently weighed in on ALNY shares. Janney Montgomery Scott started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 28th. They set a “neutral” rating and a $74.00 price objective on the stock. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, October 25th. Credit Suisse Group AG set a $145.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 30th. FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 8th. Finally, Piper Jaffray Cos. set a $106.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 6th.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 2.82% on Monday, reaching $46.53. 403,649 shares of the company’s stock traded hands. The stock’s 50 day moving average is $39.69 and its 200 day moving average is $59.81. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $109.10. The firm’s market cap is $3.99 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The business had revenue of $13.70 million for the quarter, compared to analyst estimates of $9.14 million. During the same quarter in the prior year, the firm earned ($0.91) EPS. The firm’s quarterly revenue was up 116.7% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($4.81) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/28/alnylam-pharmaceuticals-inc-alny-receives-consensus-rating-of-buy-from-brokerages.html.
In other news, Director David E. I. Pyott bought 27,900 shares of the stock in a transaction that occurred on Thursday, October 13th. The shares were acquired at an average cost of $37.00 per share, for a total transaction of $1,032,300.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. Calvert Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 36 shares during the last quarter. CIBC Asset Management Inc increased its position in Alnylam Pharmaceuticals by 1.1% in the second quarter. CIBC Asset Management Inc now owns 4,119 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 46 shares in the last quarter. IBM Retirement Fund increased its position in Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 76 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 87 shares in the last quarter. Finally, Fayerweather Charles increased its position in Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 140 shares in the last quarter. Institutional investors and hedge funds own 89.81% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.